'Abivax (ABVX) Emerges as Top M&A Target in Biotech Sector: Truist'

 

• Abivax (ABVX, Financial) is a prominent acquisition target for 2026, leading investor interest with 44% mentions.
• The company's stock has surged by 1,600% year-to-date, driven by promising results for its ulcerative colitis treatment, obefazimod.
• Truist Securities maintains a "Buy" rating on Abivax with a target price of $140.

French biotechnology firm Abivax (ABVX) has been identified as the leading acquisition target in 2026, as per a Truist Securities survey. Garnering 44% of investor mentions, Abivax leads the pack, fueled by a 1,600% year-to-date stock surge and promising results for its ulcerative colitis treatment, obefazimod. Eli Lilly (LLY) is reportedly interested in a potential acquisition. Truist maintains a "Buy" rating with a $140 target on Abivax. In contrast, Madrigal Pharmaceuticals (MDGL) is viewed as the least likely acquisition target.

https://www.gurufocus.com/news/3233281/the-1300-biotech-shockwave-that-turned-500-million-into-8-billion